(MedPage Today) — Physicians who see more socially disadvantaged and nonwhite patients received overall lower-quality performance ratings — while doctors who see fewer such patients received higher rankings, researchers found.
No Comments »
Filed under: General Health News
(MedPage Today) — Federal spending of embryonic stem cell (ESC) research will remain off-limits for now, a federal judge ruled, dealing yet another blow to the Obama administration’s efforts to support such research.
No Comments »
Filed under: General Health News
(MedPage Today) — One in five U.S. adults continues to smoke tobacco — a percentage that hasn’t budged since 2005 — suggesting that more aggressive efforts are needed to reduce smoking-related diseases and deaths, the CDC said.
No Comments »
Filed under: General Health News
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) [...]
No Comments »
Filed under: Pharmacy News
MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.
No Comments »
Filed under: Pharmacy News
MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.
No Comments »
Filed under: Pharmacy News
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled “Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent,” was published in the premier [...]
No Comments »
Filed under: Pharmacy News
Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent’s fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
No Comments »
Filed under: Pharmacy News
Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.
No Comments »
Filed under: Pharmacy News
Plexxikon today announced publication of key data in this week’s edition of Nature demonstrating that the high degree of selectivity of PLX4032 (RG7204) enables substantial RAF/MEK/ERK pathway inhibition, which may be necessary to achieve significant tumor shrinkage and clinical response in patients with BRAF mutant melanoma.
No Comments »
Filed under: Pharmacy News
